Journal article icon

Journal article

Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates.

Abstract:

Cholinergic replacement therapy for Alzheimer's disease using existing cholinesterase inhibitors is compromised by short duration, meagre benefits restricted to subgroups of patients, and peripheral toxicity. Heptyl physostigmine is a lipophilic carbamate derivative of physostigmine. In rhesus monkeys, heptyl physostigmine (0.2-0.9 mg/kg i.m.) fully reversed a scopolamine-induced cognitive impairment. Following oral administration in squirrel monkeys, heptyl physostigmine (8 mg/kg) induced lo...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Rupniak, NM More by this author
Brazell, C More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Experimental Psychology
Expand authors...
Journal:
Journal of the neurological sciences
Volume:
107
Issue:
2
Pages:
246-249
Publication date:
1992-02-05
DOI:
EISSN:
1878-5883
ISSN:
0022-510X
URN:
uuid:1733eaa0-4373-4d39-a814-cd5de6b76774
Source identifiers:
10495
Local pid:
pubs:10495

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP